“Proceeds will be used to enhance our menu and service offerings to our physician clients in the prenatal and broader women’s health market on a national scale,” Harry Stylli, executive chairman and founder of San Diego-based Progenity, said in a press release. “We shall continue to invest in new assets to strengthen our internal innovation and commercial efforts.”

Progenity’s platform might be used to orally deliver new therapeutic agents and proteins to the GI tract. As part of its precision medicine portfolio, the company is developing molecular diagnostics for small intestine bacterial overgrowth (SIBO), microbiome analytics for both the upper and lower GI tract and consumer health nutrition applications. These could be used to treat IBDs, irritable bowel syndrome, fatty liver disease and gastrointestinal cancers.

Progenity, known for women’s health molecular testing, has a pipeline of proprietary tests and therapeutics currently under development for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and non-invasive prenatal testing.

“We are excited to continue to support Progenity’s growth in patient-focused diagnostics and therapeutics,” said Jeffrey A. Ferrell, managing partner of Athyrium. “The platform the team has built is a testament to the company’s vision in women’s health and the promise of their growing oncology and gastroenterology franchises. With this financing, we believe that the company will be well capitalized to execute on its internal pipeline and business development opportunities.”

Disclaimer:

IBD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more